ClinicalTrials.gov posted results on 15 September 2026 for a completed Phase 3 trial of orforglipron in participants with type 2 diabetes inadequately controlled with metformin. Among the reported groups, HbA1c fell by 2.16 percentage points with 36 mg of orforglipron and by 1.11 percentage points with 7 mg of semaglutide.
Background
The study evaluated orforglipron, also identified in the record as LY3502970, against oral semaglutide in participants with type 2 diabetes whose glycemic control remained inadequate with metformin. The supplied data describe the study as an assessment of efficacy and safety; they do not provide mechanism details, prior approvals, or prevalence figures.
Trial design
This Phase 3 study, identified as NCT06045221, enrolled 1,698 participants with type 2 diabetes and was listed as completed. The study lasted around 61 weeks and included orforglipron and semaglutide intervention groups. The reported primary outcome assessed change from baseline in HbA1c, including non-inferiority comparisons between 12 mg and 36 mg of orforglipron and 7 mg and 14 mg of semaglutide. The record also reported the percentage of participants achieving HbA1c below 7.0%.
Key results
Least-squares mean HbA1c changes were -1.91 percentage points with 12 mg of orforglipron, with a standard error of 0.058, and -2.16 percentage points with 36 mg, with a standard error of 0.051. The corresponding changes were -1.11 percentage points with 7 mg of semaglutide, with a standard error of 0.063, and -1.45 percentage points with 14 mg, with a standard error of 0.061.
HbA1c below 7.0% was achieved by 80.04% of participants receiving 12 mg of orforglipron and 85.41% receiving 36 mg. The corresponding figures were 54.63% with 7 mg of semaglutide and 66.12% with 14 mg.
Mixed-model analyses reported least-squares mean differences of -0.71, -0.79, -0.46, -1.04, and -0.46, with each listed at p=0.001. The reported 95% confidence intervals ranged from -0.96 to -0.62, -0.86 to -0.55, -0.62 to -0.29, and -1.20 to -0.88, according to the individual analyses.
What this means
In this completed trial, the posted results showed greater HbA1c reductions and higher proportions below 7.0% in the orforglipron groups than in the corresponding semaglutide groups. The record presents non-inferiority and superiority analyses, but the supplied data do not identify which comparison corresponds to each listed confidence interval. No adverse-event summary was provided.
Source
Source: ClinicalTrials.gov, registry results for the completed Phase 3 study “A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin,” posted 15 September 2026. Available at clinicaltrials.gov/study/NCT06045221.